Anlon Healthcare has moved to expand its footprint in the pharmaceutical intermediates and active pharmaceutical ingredients (API) space by executing share swap agreements for two target entities. On August 8, 2026, the company signed deals to acquire up to 32.52% stake in Apiqo Organics Private Limited (AOPL) and up to 43.33% stake in Bizotic Lifescience Private Limited (BLPL). The transactions, valued at approximately ₹116.52 crore and ₹36.78 crore respectively, will be settled through the preferential allotment of Anlon Healthcare’s equity shares, preserving its cash reserves while securing strategic supply chain synergies.

The acquisitions qualify as related party transactions under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as promoters and directors are common across the entities. Both deals are structured on an arm’s length basis and require listing approvals from stock exchanges for the newly issued shares. The Board of Directors had previously intimated these proposals in a meeting held on July 30, 2026.

Deal Structure and Consideration

The consideration for both acquisitions will be discharged via share swaps at predetermined exchange ratios, with no cash outflow expected from Anlon Healthcare. For Apiqo Organics, the company will issue up to 45,16,200 equity shares at a price of ₹258 each. For Bizotic Lifescience, it will issue up to 22,99,000 equity shares at ₹160 each.

In total, Anlon Healthcare proposes to issue up to 8,58,83,617 equity shares with a face value of ₹2 each. The share exchange ratio is set at [1:14.45] for AOPL shareholders and [1:8.96] for BLPL shareholders. Any fractional entitlements will be rounded off to the nearest whole equity share.

Target Company Profiles

Apiqo Organics Private Limited, incorporated on December 1, 2025, following conversion from a partnership firm, manufactures pharmaceutical intermediates, industrial, fine, and inorganic chemicals. Its turnover surged from ₹977.78 lakh in FY24-25 to ₹7,254.11 lakh in FY25-26, indicating rapid scaling. Bizotic Lifescience Private Limited, incorporated in April 2015, specializes in manufacturing and exporting pharmaceutical drugs, APIs, and providing contract research and manufacturing services. Its turnover grew from ₹380.39 lakh in FY23-24 to ₹3,126.64 lakh in FY25-26.

Timeline and Regulatory Approvals

Both acquisitions are subject to customary closing conditions and shareholder acceptance of the share swap proposals. The company expects to complete the acquisitions within 90 days from the signing date or as mutually agreed. Listing and trading approvals from stock exchanges are required for the preferential issue of shares. The disclosures were made pursuant to Regulation 30 read with Part-A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

What the Numbers Show

The aggressive expansion strategy highlights Anlon Healthcare’s focus on vertical integration within the pharma supply chain. By acquiring controlling or significant minority stakes in API and intermediate manufacturers, the company aims to secure critical material supplies and enhance operational efficiency. The use of share swaps instead of cash preserves liquidity, though it dilutes existing shareholders; promoters Punitkumar Rameshbhai Rasadia and Meet Atulkumar Vachhani will see their holdings increase from 18,59,20,000 and 9,40,80,000 shares to approximately 20,43,39,402 and 10,34,31,099 shares respectively, assuming full acceptance by all target company shareholders.

Anlon Healthcare Limited has published the audio recording of its earnings conference call for the first quarter of fiscal year 2026-27 (Q1FY27), allowing investors and analysts to review management’s discussion on the company’s audited financial results. The call, held on August 6, 2026, focused on performance metrics for the quarter ended June 30, 2026, providing a direct channel for stakeholders to assess the firm’s operational health without relying solely on written filings.

The publication of the recording fulfills the company’s disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates that listed entities make investor interactions transparent and accessible to ensure equitable information distribution across all market participants.

Call Details and Access

The earnings call took place on Thursday, August 6, 2026, at 4:00 PM IST. It was conducted virtually via Zoom, with logistics managed by ConfideLeap Partners. The audio recording is now hosted on Anlon Healthcare’s official website, ensuring permanent accessibility for review.

Management Participation

Punitkumar Rameshbhai Rasadia, Managing Director of Anlon Healthcare Limited, led the management team during the interaction. As the primary executive spokesperson, he addressed queries regarding the company’s financial standing and operational updates for the quarter. His DIN is 06696258.

Regulatory Compliance

The company emphasized that all statements made during the call were based on existing public disclosures. Investors were advised that any forward-looking statements included in the discussion are subject to risks and uncertainties, including changes in the economic environment. Actual results may differ from those implied in such projections, and the company disclaims responsibility for actions taken based on these forward-looking statements.